Department of Medical Oncology, Dr. B.R.A. Institute Rotary Cancer Hospital, All India Institute of Medical Sciences, New Delhi, India.
Department of Medical Oncology, Dr. B.R.A. Institute Rotary Cancer Hospital, All India Institute of Medical Sciences, New Delhi, India.
Curr Probl Cancer. 2020 Aug;44(4):100540. doi: 10.1016/j.currproblcancer.2020.100540. Epub 2020 Jan 23.
Identification of noninvasive blood-based biomarkers is of utmost importance for the early diagnosis and predicting prognosis of advance stage lung cancer patients. MicroRNAs (miRNAs) has been implicated in numerous diseases, however, their role as diagnostic and prognostic biomarkers in Indian lung cancer patients has not been evaluated yet.
For the identification of differentially expressed miRNAs in the serum of non-small cell lung cancer (NSCLC) patients, we performed small RNA sequencing. We validated the expression of 10 miRNAs in 75 NSCLC patients and 40 controls using quantitative reverse transcription polymerase chain reaction (PCR). miRNA expression was correlated with survival and therapeutic response.
We identified 16 differentially expressed miRNAs in the serum of NSCLC patients as compared to controls. We observed significant downregulation of miR-15a-5p, miR-320a, miR-25-3p, miR-192-5p, let-7d-5p, let-7e-5p, miR-148a-3p, and miR-92a-3p in the serum of NSCLC patients. The expression of miR-375 and miR-10b-5p was significantly downregulated in lung squamous cell carcinoma patients than controls. The expression of miR-320a, miR-25-3p, and miR-148a-3p significantly correlated with stage. None of the miRNAs were correlated with survival outcome and therapeutic response.
We conclude that the relative abundance of miRNAs in serum may be explored for the development of miRNA-based assays for better diagnosis and prognosis of NSCLC. Moreover, further studies are warranted to elucidate the role of some of the less explored miRNAs, such as miR-375 and miR-320a, in the pathogenesis of NSCLC.
鉴定非侵入性血液生物标志物对于早期诊断和预测晚期肺癌患者的预后至关重要。微小 RNA（miRNA）与许多疾病有关，然而，它们在印度肺癌患者中的诊断和预后生物标志物作用尚未得到评估。
为了鉴定非小细胞肺癌（NSCLC）患者血清中差异表达的 miRNA，我们进行了小 RNA 测序。我们使用定量逆转录聚合酶链反应（PCR）在 75 名 NSCLC 患者和 40 名对照中验证了 10 个 miRNA 的表达。miRNA 表达与生存和治疗反应相关。
与对照组相比，我们在 NSCLC 患者的血清中鉴定出 16 个差异表达的 miRNA。我们观察到 miR-15a-5p、miR-320a、miR-25-3p、miR-192-5p、let-7d-5p、let-7e-5p、miR-148a-3p 和 miR-92a-3p 在 NSCLC 患者的血清中显著下调。miR-375 和 miR-10b-5p 在肺鳞癌患者中的表达明显低于对照组。miR-320a、miR-25-3p 和 miR-148a-3p 的表达与分期显著相关。没有一个 miRNA与生存结果和治疗反应相关。
我们的结论是，血清中 miRNA 的相对丰度可能被探索用于开发基于 miRNA 的检测方法，以更好地诊断和预测 NSCLC。此外，需要进一步研究来阐明一些研究较少的 miRNA（如 miR-375 和 miR-320a）在 NSCLC 发病机制中的作用。
